Compared with IDC patients, MBC patients had less lymph node metastasis, an earlier stage, a higher rate of hormone receptor positivity and a lower expression rate of HER2. The gene discussed is ERBB2; the disease is metastatic malignant neoplasm in the lymph nodes.